Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00200148
Other study ID # 04-004
Secondary ID
Status Completed
Phase Phase 3
First received September 12, 2005
Last updated March 4, 2015
Start date March 2004
Est. completion date October 2011

Study information

Verified date March 2015
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

With a major liver or pancreas operation, there is a chance that one will require a transfusion of blood products (either red blood cells or plasma). This may be necessary during the operation or a few days after surgery. The surgeons at Memorial Sloan-Kettering Cancer Center perform a very large number of liver or pancreas resections every year and have pioneered techniques that minimize bleeding during the operation. Even so, liver or pancreas operations such as the one that will be undergone carry a 50% chance of requiring a transfusion. A technique that might lower the need for transfusions is called acute normovolemic hemodilution (ANH). ANH was first introduced over twenty years ago and has been used in many types of operations, including liver or pancreas resection. The studies done on ANH at other hospitals suggest that it may help conserve blood. Researchers at Memorial Sloan-Kettering Cancer Center are conducting a study to determine if ANH is better than the 'standard technique' that is currently used in all patients. The purpose of this study is to find out which of the two techniques is better.

The purpose of the study is to see if ANH lowers the need for the transfusion of blood products during and after liver or pancreas resection.

The second purpose of the study is to see how ANH changes the length of the operation, the length of time one spends in the hospital, and the complication rate after surgery. The researchers will also see if ANH requires any changes in the administration of anesthesia.


Description:

Despite improvements in peri-operative outcome, major hepatic resection and pancreaticoduodenectomy remains associated with a high risk of major blood loss and perioperative blood transfusion.The risks associated with allogeneic blood transfusions are well-known, including immunosuppression, incompatible transfusion, and transmission of infectious agents. Clearly, efforts to reduce the use of allogeneic blood products are warranted in order to avoid potential transfusion-related complications, reduce hospital cost and avoid periods of critical blood shortage.

ANH is an approach to blood conservation that involves removal of whole blood from a patient immediately prior to an operation that is likely to be associated with significant blood loss. Following blood removal, euvolemia is restored with crystalloid and/or colloid. The harvested blood, which has a greater red cell mass than the blood lost intraoperatively, is re-infused as needed during the procedure or at the completion of the operation. ANH is more attractive than preoperative autologous blood donation for several reasons: it is technically and logistically much simpler, it requires no special equipment and costs less (no storage or administrative costs), it is associated with a lower chance of administration error, it requires no obligate pre-operative delay and is not associated with a waste of autologous units. In addition, because coagulation factors are preserved and later re-infused, ANH may reduce the need for post-operative fresh frozen plasma (FFP). Additionally, ANH may have an impact on low CVP anesthetic management during partial hepatectomy, which is standard at MSKCC and at many other centers.

The present study will help elucidate the efficacy of ANH as a means of reducing the allogeneic transfusion rate in patients undergoing major hepatic resection. If shown to be effective in reducing the use of allogeneic blood products, ANH will not only impact the current practice of hepatic resectional surgery but may also change current practice in other surgical disciplines.

This will be a prospective randomized study. Eligible patients will be consented for the trial prior to the operation.


Recruitment information / eligibility

Status Completed
Enrollment 372
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (>18 years).

- Pre-operative hemoglobin concentration >= 11 mg/dl (males); >= 10 mg/dl (females) within 14 days of registration.

- Patients scheduled for resection of 3 or more liver segments for any indication, with or without other planned procedures or patients scheduled for pancreaticoduodenectomy

Exclusion Criteria:

- A history of active coronary artery disease. Patients with a history of coronary artery disease will be eligible if they have had a cardiac stress study showing no reversible ischemia and normal left ventricular (LV) function within 30 days of operation.

- A history of cerebrovascular disease.

- A history of congestive heart failure.

- A history of uncontrolled hypertension.

- A history of restrictive or obstructive pulmonary disease.

- A history of renal dysfunction (creatinine [Cr] > 1.8).

- Abnormal coagulation parameters (International Normalized Ratio [INR] > 1.5 not on Coumadin, or platelet count < 100,000).

- Presence of active infection.

- Evidence of hepatic metabolic disorder (bilirubin > 2 mg/dl, ALT > 75 U/L in the absence of biliary tract obstruction).

- Pre-operative autologous blood donation.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Normovolemic Hemodilution (ANH)
For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
Standard of care
An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.

Locations

Country Name City State
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine if ANH reduces the requirement for allogeneic red cell transfusions in patients undergoing major hepatic resection or pancreaticoduodenectomy compared to standard intraoperative management All patients will have their blood checked every 30 minutes during surgery Yes
Secondary To determine if ANH reduces the requirement for allogeneic FFP transfusions in patients undergoing major hepatic resection or pancreaticoduodenectomy compared to standard intraoperative management All patients will have their blood checked every 30 minutes during surgery Yes
Secondary To determine the impact of ANH on post-operative complications, length of hospital stay and operating time compared to standard intraoperative management Two weeks Yes
Secondary To assess the impact of ANH on low central venous pressure (CVP) anesthetic management during partial hepatectomy Continuous monitoring during surgery Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT02041871 - Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer N/A
Recruiting NCT06044909 - Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance
Recruiting NCT05523713 - Development and Validation of a Predictive Score for Surgical Site Infections Phase 3
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Recruiting NCT06130436 - Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy N/A
Recruiting NCT04218253 - Clinical Application of Nutrition Support Package Before Hepatectomy N/A
Recruiting NCT04559269 - Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
Completed NCT03611426 - Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy Phase 1/Phase 2
Completed NCT02817321 - Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision N/A
Recruiting NCT05598060 - Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study N/A
Completed NCT03793933 - ACS-NSQIP Calculator for Liver Surgery
Recruiting NCT03540537 - A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy N/A
Recruiting NCT06166186 - Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy N/A
Not yet recruiting NCT02758977 - Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) N/A
Completed NCT01469442 - Postoperative Biliary Fistula Prevention After Hepatectomy N/A
Completed NCT00730743 - Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection N/A
Recruiting NCT02198625 - Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication Phase 4
Completed NCT01194843 - Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations N/A
Recruiting NCT03323359 - Efficacy and Tolerability of Hemopatch After Hepatic Resection N/A